Amedisys Completes Asana Hospice Acquisition, Expands NetworkHomeMailNewsFinanceSportsEntertainmentSearchMobileMore...YAHOO_FINANCESearchSign inMailSign in to view your mailFinance HomeWatchlistsMy PortfolioScreenersPremiumMarketsIndustriesPersonal FinanceVideosNewsTechU.S. Markets closedS&P 5002,978.76-137.63(-4.42%)Dow 3025,766.64-1,190.95(-4.42%)Nasdaq8,566.48-414.29(-4.61%)Amedisys Completes Asana Hospice Acquisition, Expands NetworkZacks Equity ResearchZacksJanuary 3, 2020ReblogShareTweetShareAmedisys, Inc. AMED has completed the acquisition of Asana Hospice, a key hospice and palliative care provider. With this, the company has gained 100% of Asana’s ownership interests.Asana provides hospice care to approximately 540 patients daily across eight locations in Pennsylvania, Ohio, Missouri, Kansas and Texas. With the completion of this deal, these eight locations will now come under the hospice network of Amedisys.Per Amedisys, the buyout will prove to be a strategic fit as it will expand its reach in the hospice care business. This will pave the way for enhanced patient care, better support for clinical teams and raise more awareness of the hospice care benefits.With this recent integration, Amedisys aims to strengthen its hospice care business on a global scale. Rationale Behind the DealAmedisys is making significant efforts to broaden its hospice care base, backed by the growing general awareness about the benefits of hospice care. Asana’s acquisition, the third hospice care takeover for Amedisys in 2019, will lead to the operation of a total of 146 hospice care centers across 33 states.Industry ProspectsPer a Grand View Research report, the U.S. hospice market size was estimated at $30.5 billion in 2018 and is expected to witness a CAGR of approximately 9% between 2019 and 2026. Factors like rising elderly population and increasing incidences of chronic as well as age-related diseases are expected to drive the market.Given its market potential, the deal was closed at the right time.Recent DevelopmentsIn November 2019, Amedisys collaborated with nVoq, a provider of HIPAA compliant speech recognition solutions for the healthcare industry. The partnership will leverage nVoq's technology platform within Amedisys' home health and hospice business.Additionally, Amedisys acquired the RoseRock Healthcare in April 2019 and Compassionate Care Hospice in February 2019.Price PerformanceShares of Amedisys have surged 45.4% in the past year against the industry’s 16.2% decline.Zacks Rank & Other Key PicksCurrently, the company carries a Zacks Rank #2 (Buy).Some other top-ranked stocks from the broader medical space are Haemonetics Corporation HAE, Vapotherm, Inc VAPO and Medtronic plc MDT.Haemonetics currently has a Zacks Rank #1 (Strong Buy) and a projected long-term earnings growth rate of 13.5%. You can see the complete list of today’s Zacks #1 Rank stocks here.Vapotherm’s long-term earnings growth rate is estimated at 49.5%. The company currently carries a Zacks Rank of 2.Medtronic’s long-term earnings growth rate is expected at 7.4%. It is currently Zacks #2 Ranked.Biggest Tech Breakthrough in a GenerationBe among the early investors in the new type of device that experts say could impact society as much as the discovery of electricity. Current technology will soon be outdated and replaced by these new devices. In the process, it’s expected to create 22 million jobs and generate $12.3 trillion in activity.A select few stocks could skyrocket the most as rollout accelerates for this new tech. Early investors could see gains similar to buying Microsoft in the 1990s. Zacks’ just-released special report reveals 8 stocks to watch. The report is only available for a limited time.See 8 breakthrough stocks now>>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Medtronic PLC (MDT) : Free Stock Analysis Report Haemonetics Corporation (HAE) : Free Stock Analysis Report Amedisys, Inc. (AMED) : Free Stock Analysis Report Vapotherm, Inc. (VAPO) : Free Stock Analysis Report To read this article on Zacks.com click here. Zacks Investment ResearchReblogShareTweetShareRecently ViewedYour list is empty.What to Read NextLeap Venture Studio takes a leap on pet startupsAmerican City Business JournalsMusic Could Help Your Cat Relax at the Vet, Study SaysBetter Homes & GardensRichard Branson’s Wealth Falls to Earth as Virgin Galactic SputtersBloombergA drug shortage due to the coronavirus is a 'considerable risk:' Fmr. FDA deputy commissionerYahoo Finance VideoBiocontainment expert on coronavirus: There's no need for average people to panic yetYahoo FinanceAmid coronavirus, bitcoin has fallen 6% this week to below $8,800Yahoo FinanceEl-Erian: The Fed will cut rates in March, if not beforeYahoo Finance VideoHere are 5 reasons the stock market is having its worst decline since 2008, and only one of them is the coronavirusMarketWatchMost face masks won’t protect you from the coronavirusYahoo FinanceStock market live updates: Dow drops 1190 points amid coronavirus fears, S&P 500 sees fastest correction in historyYahoo FinanceDon’t buy the stock dip yet, says Goldman as it warns coronavirus will wipe out earnings growth this yearMarketWatchCoronavirus-induced stock selloff means IPO market is 'on holiday': veteran IPO analystYahoo FinanceMarket Watcher: Over six months we will see the markets higher Yahoo Finance VideoOil’s Worst Week Since 2014 Puts Pressure on OPEC+ to RespondBloombergStock market live updates: Stock futures climb after historic rout; coronavirus fears persistYahoo FinanceSomething 'dangerous' is happening beneath the surface of the market selloffYahoo Finance